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Abstract
Background and Aim: Mesangiocapillary glomerulonephritis (MCGN) is a common cause of chronic kidney disease in
developing countries. Data on the renal outcome of patients with idiopathic MCGN is limited. The aim of this study is to
investigate the outcome of patients with idiopathic MCGN presenting to the Groote Schuur Hospital (GSH) Renal Unit in
Cape Town.
Materials and Methods: A retrospective study of patients with idiopathic MCGN followed up at our clinic. Seventy-nine
patients with no identifiable cause of MCGN were included for analysis. A composite renal outcome of persistent doubling
of serum creatinine or end stage renal disease (ESRD) was used. Kaplan Meier survival and Cox regression analysis were used
to assess survival and identify factors predicting the outcome.
Results: The mean age at biopsy was 33.9613.6 years and 41.8% were black. Mean duration of follow up was 13.5618.8
months. Twenty-three patients (34.2%) reached the composite endpoint. Overall, median renal survival was 38.7611.7
months (95% CI 15.7–61.8) with 2-year and 5-year renal survival of 61% and 40.3% respectively. No significant difference was
found for renal survival between males and females, treatment or non-treatment with immunosuppression, presence or
absence of crescents or histological type of MCGN (p.0.05). On univariate Cox-regression analysis, factors found to be
associated with the outcome were the estimated glomerular filtration rate at biopsy (OR 0.97 [95%CI: 0.95–0.99], p,0.0001),
black race (OR 3.03 [95%CI: 1.27–7.21], p = 0.012) and presence of interstitial fibrosis in the biopsy (OR 2.64 [95%CI: 1.07–
6.48], p = 0.034). Age, systolic blood pressure and attaining complete or partial remission approached significant values with
the endpoint.
Conclusions: The outcome of idiopathic MCGN in Cape Town is poor and requires further prospective studies to improve
our understanding of this common disease.
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Introduction
Mesangiocapillary glomerulonephritis (MCGN; also known as
membranoproliferative GN [MPGN]) is a histological pattern of
glomerular injury characterized by mesangial hypercellularity,
increased mesangial matrix and thickening of glomerular capillary
walls secondary to subendothelial deposition of immune complex-
es and/or complement factors, cellular entrapment, and new
basement membrane formation [1,2]. MCGN has traditionally
been divided into three distinct morphological types: type I
(classical MCGN), is characterized by the presence of subendo-
thelial deposits of immune complexes; type II MCGN (dense
deposit disease), characterized by the presence of dense deposits in
the basement membrane and type III MCGN, (considered as a
variant of type I) and characterized by the presence of additional
subepithelial deposits.
MCGN is a common cause of glomerulonephritis and the
nephrotic syndrome in many low to middle income countries but
especially in Africa [3–8]. In Romania, MCGN was the most
frequent primary glomerulonephritis (GN) and was responsible for
29.4% of all primary glomerulonephritides reported from 1995 to
2004 [3]. In a previous study from our centre, we reported MCGN
to account for 20.4% of all primary GN with 90.4% of cases being
type I MCGN [6]. However, IgA nephropathy remains the most
common primary glomerular disease reported from many
developed countries where the occurrence of primary MCGN
has steadily declined in recent decades [9–12]. Although the
‘‘hygiene hypothesis’’ [13,14] may explain some of the differences
in prevalence of glomerular diseases seen in emerging and
PLOS ONE | www.plosone.org 1 November 2014 | Volume 9 | Issue 11 | e113302
developed countries, results from recent research in this field has
now made some authors to question the existence of idiopathic
MCGN [15]. Their doubt is predominantly borne out of advances
in methods of analysis of biopsy specimens and a more thorough
and detailed evaluation of patients to identify possible causes of so-
called idiopathic MCGN [15]. However, these studies have been
published from high income countries where IgAN is still
predominant. Sethi et al have therefore proposed a new
classification for MCGN based on immune complex deposition
(with or without complement) and sole complement deposition in
the glomerulus denoting dysregulation of the alternative pathway
of complement [16] (see Figure S1 and Figure 2).
The treatment recommendation of the KDIGO on the use of
immunotherapies in idiopathic MCGN is only limited to cases in
which crescents are present [17] and treatment of adults with the
disease is often unrewarding as approximately 60% of patients will
progress to end-stage renal disease (ESRD) within 10 years [18–
20]. Given that so-called idiopathic MCGN is the most frequent
primary GN seen in our population, the aim of this study is to
report on the outcome of patients in Cape Town with idiopathic
MCGN and to identify the factors that predict renal outcomes in
such patients who are longitudinally followed up in our centre.
Materials and Methods
Ethics Statement
The study received approval from the Human Research Ethics
Committee (HREC REF: 227/2012) of the University of Cape
Town. All patient records/information was anonymized and de-
identified prior to analysis.
Study population
Hospital records of patients who had a kidney biopsy performed
between January 2000 to December 2011 and who were
diagnosed with idiopathic MCGN and followed up at the renal
clinic at Groote Schuur Hospital Cape Town were retrieved for
retrospective collection of data. The written records and the
electronic records of these patients were rigorously assessed in
order to exclude patients with MCGN with possible secondary
cause. All selected patients were proven to have tested negative for
common viral infections (HIV, Hepatitis B and C), other
commonly encountered infections (such as mycobacterium tuber-
culosis, syphilis) and autoimmune diseases (lupus and rheumatoid
arthritis). As these patients were not acutely ill at presentation or
showing evidence for any chronic infections, tests for malaria,
schistosomiasis, leprosy among other possible infections that have
been reported to be associated with MCGN were not performed;
and although these infections are unusual in Cape Town, the
patients never manifested any features of them during follow up.
Serum protein electrophoresis, urine protein electrophoresis and
bone marrow biopsy were not clinically indicated and were thus
not performed in our patients. We identified 85 patients with
complete records and with no known secondary causes of MCGN
but excluded 6 patients whose biopsies only had C3 complement
deposits alone.
Data Collection
Demographic, clinical and biochemical records of patients
included in the study were obtained at the time of biopsy and
during follow-up visits to the renal clinic. Data collected therefore
included age at time of biopsy, gender, indication for biopsy,
duration of follow up, serial recorded blood pressures (systolic and
diastolic) and various laboratory measurements (serum albumin,
creatinine, cholesterol, complements (C3 and C4 – expressed as
normal or low) and proteinuria [g/24 hrs]. The racial grouping of
our patient population was categorized as Black Africans and non-
Black Africans (to include patients of mixed ancestry and Whites).
The estimated glomerular filtration rate was calculated using the
Modification of Diet in Renal Disease (MDRD) formula [21].
Treatment received by the patients was also recorded.
Histology
Light microscopic and immunohistochemical features of the
renal biopsies were noted and recorded. Histological data collected
included number of glomeruli per biopsy, percentage of sclerosed
glomeruli reported, degree of interstitial fibrosis (none, mild,
moderate or severe), presence of crescentic lesions and type of
deposit present on immunohistochemical analysis (IgA, IgG, IgM
or C3). All patients included had immune complex type MCGN
(immune complex deposits were present with or without comple-
ment deposit) according to the newly proposed classification of
Sethi et al [16]. Those with only C3 deposits were excluded in the
analysis. Electron microscopic examination of all biopsy specimens
was performed. All the histological specimens were reviewed by
one pathologist (M.D.).
Definitions used in this study
Blood pressure. Hypertension was defined as systolic BP
(SBP) persistently $140 mmHg and/or diastolic BP (DBP) $
90 mmHg or if on treatment with anti-hypertensive medications
[22]. Blood pressure at biopsy and average BP during follow up
visits were recorded.
Remission. As there is no guideline for defining remission in
MCGN, we used the following criteria and categorized patients
into 3 groups: complete remission (CR), partial remission (PR) or
no remission (NR) [23]:
N CR was defined as proteinuria of ,0.2 g/day with stable
eGFR if normal at baseline or increase in eGFR by 25% if
abnormal at baseline.
N PR was defined as reduction in proteinuria (for proteinuria
between 0.2 and 2.9 g) and stable eGFR if normal at baseline
or increase in eGFR by 25% if abnormal at baseline.
N NR was defined as persistent proteinuria of $3 g/day or
progressive or worsening renal impairment.
Study end-point
The composite end point of this study was persistent doubling of
the serum creatinine over the baseline value or end-stage renal
disease (ESRD). For patients who reached the end point, the
period of follow-up was the interval between first renal biopsy and
the time the end point was reached.
Statistics
The data were analyzed using IBM SPSS Statistics 21 software
(SPSS, Chicago, IL). Categorical variables were presented as
percentages and continuous variables as means 6 SD. Compar-
ison was made between those reaching the end-point and those not
reaching the end-point using the Student’s t-test, chi-square test or
Fisher’s exact test. Estimate of survival was done using the
Kaplan–Meier survival method. Renal survival with time to
ESRD was assessed using Kaplan–Meier estimates and log-rank
test for comparison of survival estimates between groups.
Univariate analysis was performed using Cox regression analysis
to assess the association between relapse-free survival and
explanatory variables. Significant P-value was taken as P,0.05.
MCGN in Cape Town
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Results
Baseline characteristics of the patients
There were a total of 79 patients eligible for inclusion in the
study with renal biopsy diagnosis of MCGN and with no clinical or
biochemical evidence for a secondary cause of MCGN. The mean
age of all the patients was 33.9613.6 years with 74.7% of the
patients being males. Racial distribution of the subjects was
41.8%, 54.4% and 3.8% for blacks, patients of mixed ancestry and
whites respectively. We observed that 20.3% of the patients were
either actively abusing substance (predominantly methamphet-
amines – called ‘‘Tik’’ in Cape Town) or were referred to us from a
correctional services department for treatment. Nephrotic syn-
drome was by far the most frequent indication for renal biopsy in
77.9%. Other features at time of biopsy are shown in Table 1.
Histological characteristics of the renal biopsies
Table 2 summarizes the histological features of the biopsies.
The average number of glomeruli per biopsy was 16.5610.5 with
an average of 6.2% glomeruli reported as sclerosed. In 63.5% the
interstitium was completely normal with no evidence of fibrosis at
the time of biopsy; severe interstitial fibrosis was present in 4.1%.
IgM deposits (59.4%) and C3 deposits (69.8%) were more
frequently seen.
Comparison of the features of patients reaching or not
reaching end-point
Twenty-three of 79 patients (34.2%) reached the end-point.
There were more black African patients reaching end-point than
non-black patients (60.9% vs 33.9%; p = 0.044). Average of all
systolic and diastolic blood pressures during follow up visits were
significantly higher in those who reached the end-point than in
those who did not reach the end-point (p,0.05) (Table 3).
However, SBP and DBP at initial presentation, although higher
in those reaching the end-point were not significantly different. A
significantly higher proportion of patients had attained a complete
or partial remission at six months after diagnosis in those not
reaching end-point than in those who did (36.2% vs 4.8%;
p = 0.007).
The frequencies of immune (IgA, IgG and IgM) or complement
(C3) deposits observed in the biopsies were not significantly
different in both groups. Presence of any interstitial fibrosis (mild,
moderate or severe) was significantly higher in the group reaching
end-point (56.5% vs 30.4%; p = 0.041); although there were more
patients in the group that reached end-point with crescentic lesion
present on biopsy, this was not significantly different between the 2
groups. Of all the biochemical features, only serum creatinine (and
estimated GFR) at presentation were significantly different
between the 2 groups (Table 4). Those who reached the end-
point had a significantly higher value of serum creatinine
(p = 0.001) at the time of renal biopsy (which was usually the first
presentation of the patient). There were more patients in the end-
Table 1. Demographic, clinical and biochemical features of all the patients.
Baseline characteristics (n = 79) Value
Mean age (years) 33.9613.6
Gender (Male) (%) 74.7
Ethnicity (%):
- Blacks 41.8
- Mixed ancestry 54.4
- Whites 3.8
Mean duration of follow-up (months) 13.5618.8
Hypertension at biopsy (%) 65.8
Oedema present at biopsy (%) 84.8
History of substance abuse or incarceration (%) 20.3
History of schizophrenia (%) 5.1
SBP at biopsy (mmHg) 159.9630.1
DBP at biopsy (mmHg) 95.8617.8
Indication for renal biopsy (%):
- Nephrotic syndrome 77.9
- Nephrotic-nephritic syndrome 10.3
- AKI 5.9
Serum albumin at biopsy (g/L) 25.967.3
Serum cholesterol at biopsy (mmol/L) 6.762.3
Serum creatinine at biopsy (mmol/L) 180.66166.8
Estimated MDRD GFR at biopsy (ml/min/1.73 m2) 65.1635.2
Proteinuria at biopsy (g/24 hrs) 8.266.4
Low complement C3 at biopsy (%) 15.2
Low complement C4 at biopsy (%) -
SBP – Systolic blood pressure, DBP – Diastolic blood pressure, AKI – Acute kidney injury, MDRD – Modification of diet in renal failure, GFR – Glomerular filtration rate.
doi:10.1371/journal.pone.0113302.t001
MCGN in Cape Town
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point group with low serum complement; however, this was not
significantly different from those not reaching the end-point.
As treatment often followed a conservative care approach, use
of an angiotensin converting enzyme inhibitor (ACE-i) or
angiotensin receptor blocker (ARB) was common but was not
significantly different between the 2 groups (87.0% vs 92.9%;
p = 0.409). There were more patients who reached endpoint that
received immunosuppression therapy: prednisone: 52.2% vs
25.0%; p = 0.034, pulse cyclophosphamide: 26.1% vs 8.9%;
p = 0.071, Azathioprine: 8.7% vs 3.6%; p = 0.635).
Survival Analysis
The cumulative renal survival curve is shown in Figure 1.
Overall, the median renal survival was 38.7611.7 months (95%
confidence interval [95%CI]: 15.7–61.8) with 2-year and 5-year
renal survival being 61.0% and 40.3% respectively. Kaplan-Meier
Table 2. Histological features of the renal biopsies (n = 79).
Variable Value
Number of glomeruli 16.5610.5
Interstitial fibrosis (%):
- No fibrosis 63.5
- Mild fibrosis 24.3
- Moderate fibrosis 8.1
- Severe fibrosis 4.1
Mean percentage of sclerosed glomeruli (%) 6.2
Crescentic lesions present (%) 17.1
Immunohistochemical features (%):
- IgA deposit present 18.8
- IgG deposit present 43.8
- IgM deposit present 59.4
- C3 deposit present 69.8
Ig – Immunoglobulin, C3 – Complement 3.
doi:10.1371/journal.pone.0113302.t002
Table 3. Comparison of clinical and histological factors associated with outcome.
Factors End-point p
NO (n = 56) YES (n = 23)
Age at biopsy (years) 33.0612.6 36.1616.0 0.364
Duration of follow-up (Months) 11.6617.1 17.9622.1 0.178
Gender (Male) (%) 71.4 82.6 0.398
Race (%): 0.044
- Blacks 33.9 60.9
- Non-Blacks 66.1 39.1
Hypertension at biopsy (%) 64.3 69.6 0.796
SBP at initial presentation (mmHg) 155.3629.4 167.9630.6 0.198
Average SBP at follow-up (mmHg) 141.7619.8 168.1630.1 0.003
DBP at initial presentation (mmHg) 93.4618.5 100.0616.3 0.257
Average DBP at follow-up (mmHg) 88.4613.8 99.2619.2 0.018
Complete or partial remission at 6 months: 36.2 4.8 0.007
Histological features (%):
- IgA deposits present 22.7 21.1 1.000
- IgG deposits present 47.7 57.9 0.585
- IgM deposits present 68.2 68.4 1.000
- C3 deposits present 62.8 78.9 0.252
- Any interstitial fibrosis present (%) 30.4 56.5 0.041
- Any crescentic lesion present (%) 14.3 26.1 0.330
SBP – Systolic blood pressure, DBP – Diastolic blood pressure, Ig – Immunoglobulin, C3 – Complement 3.
doi:10.1371/journal.pone.0113302.t003
MCGN in Cape Town
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renal survival curves for differences in outcome based on race (log
rank p = 0.009), gender (log rank p = 0.995), treatment with I/V
cyclophosphamide (log rank p = 0.440) and presence or absence of
interstitial fibrosis (log rank p = 0.028) are shown in figure 2. Cox
univariate regression analysis for predictors of end-point.
Factors associated with the end-point, identified through Cox-
regression analysis are shown in Table 5. Estimated GFR at
biopsy (OR 0.97 [95%CI 0.95–0.99], p,0.0001), being of black
African descent (OR 3.03 [95%CI 1.27–7.21], p = 0.012) and
presence of interstitial fibrosis at biopsy (OR 2.64 [95%CI 1.07–
6.48], p = 0.034) were the factors identified to be associated with
the end-point. Early complete or partial remission (at six months
after renal biopsy) did not influence the renal outcome in these
patients (OR: 0.17 [95%CI: 0.02–1.27]; p = 0.084).
Discussion
The analysis of our data of patients with idiopathic MCGN in
Cape Town shows that a number of important demographic,
Table 4. Comparison of biochemical and treatment factors associated with outcome.
Factors End-point p
NO (n = 56) YES (n = 23)
Complement C3 at biopsy 1.0560.41 1.2360.62 0.311
Low complement C3 at biopsy (%) 14.3 17.4 0.706
Complement C4 at biopsy 0.3660.33 0.3760.19 0.891
Low complement C4 at biopsy (%) - - -
Serum cholesterol (mmol/L) 6.161.4 7.963.2 0.079
Serum albumin at biopsy (g/L) 26.166.9 25.268.2 0.667
Serum creatinine at biopsy (mmol/L) 124.7686.9 315.26229.0 0.001
Estimated MDRD GFR at biopsy (ml/min) 75.3630.6 40.5634.0 ,0.0001
Proteinuria at biopsy (g/day) 8.166.9 8.365.2 0.872
Treatment with ACE-i/ARB (%) 92.9 87.0 0.409
Treatment with prednisone (%) 25.0 52.2 0.034
Treatment with cyclophosphamide (%) 8.9 26.1 0.071
Treatment with Azathioprine (%) 3.6 8.7 0.635
MDRD – Modification of Diet in Renal Disease; GFR – Glomerular filtration rate; ACE-I – Angiotensin converting enzyme inhibitors; ARB – Angiotensin receptor blockers.
doi:10.1371/journal.pone.0113302.t004
Figure 1. Kaplan-Meier curve for overall renal survival in the study population.
doi:10.1371/journal.pone.0113302.g001
MCGN in Cape Town
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Figure 2. Kaplan-Meier curve for renal survival based on histological features of MCGN. (A) shows differences in outcome between Black
Africans and non-Black Africans (log rank p = 0.009); (B) shows gender differences in outcome (log rank p = 0.995); (C) differences between patients
who received treatment with cyclophosphamide and those who didn’t receive treatment (log rank p = 0.440) and (D) shows differences in outcomes
based on the presence of interstitial fibrosis in the biopsy (log rank p = 0.028).
doi:10.1371/journal.pone.0113302.g002
Table 5. Cox univariate regression analysis for predictors of the end-point.
Variable OR (95% CI) P value
Age 1.03 (0.99–1.06) 0.089
Gender (Female) 0.99 (0.33–2.99) 0.995
Estimated GFR at biopsy 0.97 (0.95–0.99) ,0.0001
Average SBP during follow-up 1.01 (0.99–1.03) 0.082
Average DBP during follow-up 1.00 (0.98–1.03) 0.982
Remission status at 6 months (CR/PR) 0.17 (0.02–1.27) 0.084
Race (Blacks) 3.03 (1.27–7.21) 0.012
Interstitial fibrosis (Present) 2.64 (1.07–6.48) 0.034
Crescent (Present) 1.66 (0.64–4.29) 0.295
Cyclophosphamide (Yes) 1.45 (0.56–3.78) 0.443
GFR – Glomerular filtration rate; SBP – systolic blood pressure; DBP – diastolic blood pressure; CR – complete remission, PR – partial remission.
doi:10.1371/journal.pone.0113302.t005
MCGN in Cape Town
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clinical and histological features may adversely predict the renal
outcome in these patients. Given that there are no published
recent outcome studies on idiopathic MCGN, this study has shown
that in comparison with previous studies, the renal outcome of
patients with idiopathic MCGN remains dismally low in
comparison to outcomes in previously published studies (Table 6)
[18–20,24–28]. Importantly, we have observed that lower
estimated GFR at presentation (often a surrogate of late
presentation), being of black African ethnicity and presence of
interstitial fibrosis in the renal histology were the predicting factors
of renal outcome in our patients. The 2-year and 5-year renal
survival was found to be low in this study.
Late presentation of patients is common in many centres in
Africa and is thought to be an important factor responsible for
disease outcome [7,29,30]. Many late presenters will have
markedly elevated serum creatinine (low eGFR) and may have
features of ureamia or be in need of dialysis at first presentation.
Late presenters may account for 36.5% of our patients having
significant interstitial fibrosis on histology (Table 2). Reasons for
late presentation are often tied to poverty (lack of transportation,
long distances to health care facility, lack of health insurance, low
level of education), cultural beliefs (visits to the traditional healer)
or due to late referral. Although in this study we did not evaluate
the duration of symptoms in our patients, many patients often
report having been ill for many weeks and in some instances many
months before presenting to hospital. In one study, late evaluation
of patients with chronic kidney disease (CKD) was reported to be
associated with greater burden and severity of comorbid disease,
black ethnicity, lack of health insurance, and shorter duration of
survival [31]. However, late presentation alone may not explain
the elevated serum creatinine as the pathogenesis of MCGN itself
(involving complement activation, capillary wall damage and
reduction in filtration at the glomerulus) may have accounted for
this. We did not exclude the possible effects of genetic factors
relative to outcome in this study; hence our finding of the black
race being associated with outcome may be put down to socio-
economic factors rather than genetic as many of the black patients
who use the public health care system in South Africa are indigent.
Although SBP and DBP during follow-up were not predictors of
the endpoint on regression analysis, they were significantly higher
in those patients reaching endpoint than those who didn’t.
Uncontrolled hypertension combined with impaired sieving
function with consequent protein overload play a pathogenic role
in the progression of CKD. The utility of adequate BP control to
reduce progression of kidney disease in diabetic and non-diabetic
CKD has been shown from various studies and is recommended
by various guidelines [21,22,32,33]. One systematic review and
meta-analysis of randomized controlled trials on the effects of
intensive BP lowering on the progression of CKD has reported
that in 5 trials that involved 1703 patients, intensive BP lowering
reduced the risk of progressive kidney failure by 27% in people
with proteinuria at baseline [34]. In one large population based
study, the odds ratios to develop progression of urine albumin
excretion during follow-up was 1.91 (95% CI 1.72 to 2.12) per 10-
mmHg increase in BP during follow-up and this was independent
of baseline BP and other biochemical and patient factors during
follow-up [35]. In our study, several patients were receiving
treatment with an agent that blocked the renin angiotensin
aldosterone pathway. Previous studies from our centre have also
highlighted inadequate control of BP as a factor for poor outcomes
in patients with proliferative and non-proliferative glomerulone-
phritis [36,37]. Poor BP control may be related to the disease
process or in some instances to poor adherence to therapy.
Emphasis on BP control in patients with MCGN may therefore be
useful in improving renal outcomes since, unlike in many other
glomerular diseases, immunosuppression has a limited role in the
treatment of patients.
Renal survival in MCGN has often been reported to be low and
with probably worse outcomes in comparison with other
glomerular diseases, probably due to lack of specific therapy for
MCGN. Recommendations from the KDIGO guideline for
treatment of MCGN are limited to cases with abnormal renal
function and are drawn mainly from small observational studies
[17]. It was interesting that treatment with immunosuppression
did not make any difference with regards to the outcome even
though there were more patients in our study who reached
endpoint that received immunosuppression (Table 4). Renal
survival in this study was found to be 61% at 2 years and 40.3%
at 5 years, much lower than for studies reported from developed
countries. Although some older studies have found type of MCGN
to predict outcome, we did not apply this to our study given the
new approach to classifying patients with MCGN [16]. However,
like some previous studies have reported, we found that any degree
of interstitial fibrosis present at time of biopsy (mild/moderate/
severe) is a poor prognostic factor for renal outcome.
Given recent publications on this subject, a major question that
this study needed to address is whether everything was done to
exclude all known secondary causes of MCGN before a labeling of
the ‘‘idiopathic’’ diagnosis. The answer to that question is ‘‘yes – as
far as was possible’’ given the clinical features of the patients at
time of presentation and during follow up. All the patients
included in this study had the immune-complex type of MCGN
hence, secondary causes will include various chronic bacterial and
viral infections, autoimmune diseases and monoclonal gammop-
athy (dysproteinaemia). All the patients included in this study
tested negative for HIV, hepatitis B and C, syphilis and did not
demonstrate serological or histological features of post-infectious
glomerulonephritis. Our patients also tested negative for cryo-
globulins and commonly occurring autoimmune diseases like SLE
and rheumatoid arthritis. As it was not clinically indicated, no
patient was tested for a dysproteinaemia and there were no
features to suggest the disease being present at time of presentation
or during the period of follow-up. Our patients typically present at
a younger age (mean age in this study is 33.9613.9 years)
compared to other studies where dysproteinaemias have been
reported [38,39]. The lack of evidence for a secondary cause of
MCGN is supported by the absence of clinical manifestation of
any chronic infection or systemic disease during the period of
follow up in our patients. However, the high frequency of patients
with IgM deposits (59.4%) in their biopsy may be suggestive of a
recent (maybe sub-clinical infection) at time of biopsy.
There still remains on our part a persistent and a renewed
concern that there is a huge gap in our understanding of this
common disease in Cape Town even though we continue to see
many ‘‘healthy’’ patients presenting with nephrotic syndrome in
whom renal histology show MCGN that is labeled as idiopathic
after a detailed and thorough assessment. It could be that we have
continued to miss a yet to be identified sub-clinical chronic
antigenaemic process possibly resulting from an environmental
exposure to drugs (substance abuse), tattoo ink or previous
incarceration from one of the correctional services department
in Cape Town all of which we have observed to be quite common
amongst these patients. Further prospective studies are required to
reprove this.
There were a number of limitations for this study. Firstly is our
inability to assess for the monoclonality of the Ig deposits at time of
biopsy. However, as our patients were young and never exhibited
clinical features to suggest monoclonal gammopathy at any time
MCGN in Cape Town
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during follow-up, this diagnosis was clinically excluded. Secondly,
given the high number of patients with intravenous drug abuse
and the common finding of IgM deposition in glomeruli, our study
is also limited by the absence of routine testing for IgG/IgM mixed
cryoglobulins. However, given that cryoprecipitates which can
occasionally be observed as hyaline-like globules were not
observed in the histological materials of these patients further
makes this unlikely. Finally, the retrospective design of this study
limited the type of data that can be collected and analyzed. This
therefore warrants a prospective study of patients with ‘‘idiopath-
ic’’ MCGN with emphasis on a more rigorous evaluation to
exclude or identify possible secondary causes. For now however,
patients identified with MCGN in whom we are unable to find a
cause, efforts to reduce proteinuria and treat BP to target will be
our major aim.
Conclusions
The outcome of idiopathic MCGN in Cape Town is poor and is
related to socio-demographic as well as to some clinical and
histological features at time of presentation. Being the most
frequent primary glomerular disease reported in Cape Town,
there is need for a prospectively designed study of idiopathic
MCGN in order to increase our understanding of its pathogenesis
and maybe find ways to its treatment.
Supporting Information
Figure S1 Glomerular features of one of our study
patients identified with immune complex type MCGN. A
– The H&E stain showing increased lobulation of the displayed
glomerulus and increased mesangial matrix; B – silver stain
showing double contours/splitting of the glomerular basement
membrane; C – F shows positive immunohistochemical stains for
C3, IgG, IgA and IgM respectively; G–I are the electron
micrographs (x 30,000) showing sub-endothelial and intramem-
branous deposits. (Courtesy Dr M Duffield and Mr. D.
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